Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Thursday, April 30, 2026 1 min read
Key Takeaway: Verastem Oncology has launched the Reimagine campaign to raise awareness about AVMAPKI® FAKZYNJA® CO-PACK, the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer. This initiative aims to educate healthcare professionals and patients about the treatment options available for this specific cancer type. The campaign reflects Verastem's commitment to advancing care for patients with RAS/MAPK pathway-driven cancers.
Market Sentiment Analysis
POSITIVE FACTORS
Launch of a new awareness campaign for a specific cancer treatment.
First FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer.
Focus on educating healthcare professionals and patients.
Full Press Release Details
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for adult patients with KRAS-mutated recurrent
Frequently Asked Questions
What is the Reimagine campaign?
The Reimagine campaign aims to raise awareness about AVMAPKI® FAKZYNJA® CO-PACK for ovarian cancer.
What is AVMAPKI® FAKZYNJA® CO-PACK?
It is the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer.
Who is the target audience for the campaign?
The campaign targets healthcare professionals and patients affected by ovarian cancer.
Which company launched the Reimagine campaign?
Verastem Oncology launched the Reimagine campaign.